AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price fell 2.4% during trading on Wednesday. The stock traded as low as $284.91 and last traded at $285.9170. 4,735,965 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 6,277,263 shares. The stock had previously closed at $292.82.
Key Headlines Impacting AbbVie
Here are a few of the latest headlines about ABBV:
- Positive Sentiment: Barclays raised its price target to $335 from $325 and maintained an Overweight rating, citing further potential after AbbVie’s shares gained 27% over the prior year. AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
- Positive Sentiment: AbbVie’s neuroscience franchise posted 19.5% operational sales growth in Q3, and the company raised its 2026 sales outlook for the segment to $13 billion—supportive signs for growth beyond its established products. How Did AbbVie’s Neuroscience Franchise Perform in Q3?
- Neutral Sentiment: AbbVie reported an update to its ABBV-2294 clinical study for rare systemic sclerosis. The available summary does not provide trial results, so the update’s potential impact on the drug’s prospects is unclear. AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis
Analysts Set New Price Targets
Several analysts have recently issued reports on ABBV shares. Guggenheim increased their price objective on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Cantor Fitzgerald boosted their target price on AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. The Goldman Sachs Group increased their price target on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research report on Friday, October 23rd. Finally, Barclays lifted their price objective on AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $299.62.
AbbVie Stock Performance
The firm has a market capitalization of $505.39 billion, a PE ratio of 49.21, a PEG ratio of 1.34 and a beta of 0.20. The company’s 50-day moving average price is $277.14 and its 200-day moving average price is $241.64.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.86 earnings per share. As a group, analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.
Insider Activity
In other news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.
Hedge Funds Weigh In On AbbVie
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in AbbVie by 0.3% during the 3rd quarter. State Street Corp now owns 82,815,387 shares of the company’s stock worth $21,663,677,000 after purchasing an additional 218,639 shares during the period. Fisher Asset Management LLC increased its stake in AbbVie by 252.6% in the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. Corient Private Wealth LP acquired a new position in AbbVie in the second quarter valued at $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of AbbVie in the second quarter valued at about $2,905,952,000. 70.23% of the stock is owned by institutional investors and hedge funds.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
